CA
NZ
UK
AU
IND
US
…
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Telomir Pharmaceuticals, Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company; public disclosures about its specific programs and commercial products are limited. Long-term growth may be driven by clinical and regulatory progress, strategic partnerships or licensing, and eventual commercialization of any lead programs, which could support upside if trials succeed and therapies address unmet needs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -10.41M | -16.53M | -13.07M | -0.85M | -0.14M |
| Net income | -10.41M | -16.53M | -13.07M | -0.85M | -0.14M |
| Selling general administrative | 8.10M | 9.64M | 0.60M | 0.02M | 0.01M |
| Ebit | - | -12.19M | - | - | - |
| Ebitda | -10.41M | 0.05M | - | - | - |
| Depreciation and amortization | - | 12.24M | - | - | - |
| Operating income | -10.54M | -12.24M | -3.94M | -0.85M | -0.14M |
| Other operating expenses | 10.54M | 12.24M | - | - | - |
| Interest expense | 0.00M | 4.34M | 1.64M | 0.00M | - |
| Interest income | 0.13M | 0.05M | - | - | - |
| Net interest income | 0.13M | -4.29M | -1.64M | 0.00M | - |
| Income tax expense | - | -16.53M | - | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 10.54M | 12.24M | 3.94M | 0.85M | 0.14M |
| Total other income expense net | 0.13M | -4.29M | -7.49M | - | - |
| Net income from continuing ops | -10.41M | -16.53M | -13.07M | -0.85M | -0.14M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 7.34M | 1.32M | 4.77M | 0.05M | 0.00M |
| Other current assets | 0.05M | 0.06M | - | - | - |
| Total liab | 1.43M | 0.68M | 1.34M | 0.99M | 0.14M |
| Total stockholder equity | 5.91M | 0.64M | 3.44M | -0.94M | -0.14M |
| Other current liab | 0.42M | 0.00M | - | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -41.01M | -30.60M | -14.06M | -0.99M | -0.14M |
| Cash | 7.29M | 1.27M | 0.00M | 0.00M | 0.00M |
| Total current liabilities | 1.43M | 0.68M | 1.34M | 0.99M | 0.14M |
| Net debt | -6.81M | -1.17M | 0.10M | - | - |
| Short term debt | 0.47M | 0.09M | - | - | - |
| Short long term debt | - | - | 0.10M | - | - |
| Short long term debt total | 0.47M | 0.09M | - | - | - |
| Other stockholder equity | 46.92M | 31.24M | - | - | - |
| Total current assets | 7.34M | 1.32M | 0.44M | 0.05M | 0.00M |
| Accounts payable | 0.54M | 0.59M | 0.71M | 0.40M | 0.02M |
| Non current assets total | 0.00M | 0.00M | 4.34M | 0.00M | 0.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Net borrowings | 0.16M | -0.10M | - | - | - |
| Total cash from financing activities | 9.71M | 6.34M | 3.86M | 0.47M | 0.12M |
| Net income | -10.41M | -16.53M | -13.07M | -0.85M | -0.14M |
| Change in cash | 6.02M | 1.26M | -0.00M | 0.00M | 0.00M |
| Begin period cash flow | 1.27M | 0.00M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 7.29M | 1.27M | 0.00M | 0.00M | 0.00M |
| Total cash from operating activities | -3.69M | -5.07M | -3.86M | -0.47M | -0.12M |
| Issuance of capital stock | 9.55M | 6.83M | 1.00M | 0.06M | 0.00M |
| Depreciation | - | 4.34M | - | - | - |
| Other cashflows from financing activities | 0.16M | -0.40M | - | - | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.59M | 0.13M | 0.11M | 0.39M | 0.02M |
| Stock based compensation | 5.29M | 6.87M | - | - | - |
| Other non cash items | 0.84M | 0.13M | 1.61M | - | - |
| Free cash flow | -3.69M | -5.07M | -3.86M | -0.47M | -0.12M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| TELO Telomir Pharmaceuticals, Inc. Common Stock |
-0.02 2.13% |
0.92 | - | - | - | 15.92 |
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | Co-Founder, Chairman & CEO | 1953 |
| Mr. Nathen Fuentes CPA | CFO, Treasurer, & Secretary | 1983 |
| Mr. Christos Nicholoudis Esq. | General Counsel & Director | 1991 |
| Mr. Erez Aminov | Chairman of the Board & CEO | 1978 |
| Mr. Andriy Mushak CPA | Chief Financial Officer | 1983 |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...